揭开肝硬化中的凝血悖论:挑战和见解
K Ferdinande1,2, S Raevens1, J Decaestecker2
1Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.
Acta clinica Belgica
|February 21, 2025
概括
肝硬化呈现出一个
科学领域:
- 肝病学和凝血科学 肝病学和凝血科学
背景情况:
- 肝病诱导复杂的静血变化,称为"再平衡的静血",容易出血或血栓形成并发症.
- 传统的凝血测试不足以评估肝硬化中的血液静止;先进的测试提供了洞察力,但缺乏对临床结果或预防的预测能力.
- 与出血障碍观点相反,肝硬化患者表现出增加的静脉血栓塞栓症风险,由"自动抗凝"神话和抗凝安全性担忧复杂化.
研究的目的:
- 为了阐明"凝血悖论"在肝硬化.
- 倡导在慢性肝病中管理出血和血栓的细微,个性化策略.
- 为了解决关于抗凝血剂在肝硬化患者的安全性和有效性的误解.
主要方法:
- 关于肝脏疾病中血液静止的当前文献的综述.
- 在肝硬化中分析传统和先进的凝血测试.
- 对肝硬化患者的血栓预防和抗凝药的证据的评估.
主要成果:
- 肝硬化涉及一个矛盾的静血状态,有出血和血栓风险.
- 低分子量肝素显示出在肝硬化中安全有效的血栓预防的前景.
- 治疗性抗凝剂可能有利于肝硬化患者的血栓事件或心房动,可能减少肝纤维化和门外高血压.
结论:
- 在肝硬化中,转向基于证据的血栓预防和个性化抗凝策略是有必要的.
- 合理的手术前规划应尽量减少不必要的血液产品输血,并优化风险管理.
- 需要进行进一步的研究,以确定晚期肝病中抗凝剂的明确指导方针.
相关概念视频
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...


